OSE Immunotherapeutics Announces Corporate Update and H1 2022 Results Sep 22, 2022 12:53PM
OSE Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer after Failure to Immune Checkpoint Inhibitors at ESMO Congress 2 Sep 5, 2022 01:30AM